Form 4: Cardio Diagnostics CEO Acquires Additional Shares
SEC Form 4 Filing
Meeshanthini Dogan, CEO of Cardio Diagnostics Holdings, Inc., reports the acquisition of 68,965 shares of common stock at $0.29 per share.
Summary
- On September 6, 2024, Meeshanthini Dogan, the CEO of Cardio Diagnostics Holdings, Inc., acquired 68,965 shares of common stock at a price of $0.29 per share.
- Following this transaction, Dogan directly owns 1,683,867 shares.
- The shares are held in an account with her spouse, the issuer's Chief Technology Officer, as joint tenants with rights of survivorship.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard regulatory filing. The CEO's purchase could be seen as a positive signal, but it's not explicitly stated as such.
Positives
- The CEO's purchase of shares may signal confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure required by the SEC for corporate insiders. It provides transparency regarding the trading activities of company executives.
Stakeholder Impact
- Shareholders may view the CEO's stock purchase as a positive sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 09/06/2024 | Date of transaction: CEO acquired shares of common stock. |
| 09/09/2024 | Date of report filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.